Gefitinib Completed Phase 2 / 3 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT01933347Third-line Treatment of Gefitinib in NSCLC Patients
NCT00891579Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations
NCT01196234Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer
NCT01017679Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
NCT00333294Phase II Iressa + Irradiation Followed by Chemo in NSCLC
NCT00409006Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
NCT00173875Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer
NCT00231465Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
NCT01037998UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer
NCT00824746Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
NCT00059722This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
NCT00198393Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
NCT00264498Phase II Iressa & Carbo/Gem in NSCLC
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NCT00256711Phase II Iressa Versus Vinorelbine (INVITE)
NCT01498562Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer